Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Telcyta: Phase II

Follow-up data from a Phase II trial in 19 evaluable patients

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE